Burney Co. Acquires 12,705 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Burney Co. grew its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 113.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 23,922 shares of the biotechnology company's stock after buying an additional 12,705 shares during the quarter. Burney Co. owned approximately 0.05% of United Therapeutics worth $8,441,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. World Investment Advisors LLC bought a new stake in United Therapeutics in the third quarter valued at $139,206,000. FMR LLC boosted its stake in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Assetmark Inc. boosted its stake in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Franklin Resources Inc. increased its position in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after buying an additional 123,929 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after buying an additional 92,240 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $378.36.

United Therapeutics Stock Down 0.8 %

NASDAQ:UTHR traded down $3.06 during trading hours on Wednesday, hitting $361.64. 284,615 shares of the stock traded hands, compared to its average volume of 261,703. The stock has a 50 day moving average price of $369.86 and a 200 day moving average price of $353.31. The company has a market cap of $16.15 billion, a price-to-earnings ratio of 15.88, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.38 EPS. Equities analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the company's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,630 shares of company stock valued at $54,371,916 over the last 90 days. Company insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.